5th BioCon China 2018 is Coming up

BioCon China

January 18, 2018

2017 was a fruitful year for global and China’s biopharmaceutical industry: PD-1/PD-L1 inhibitors prosper, biosimilars blossom, and CAR-T cell therapies debut. The investment of huge capital and gradual improvement of policies have undoubtedly made enormous progress in the field of biopharmaceuticals.


To speed up Asian Bioinnovatives and Biosimilars development and to promote industry exchange and cooperation, BioCon China 2018, as the largest and the most professional annual meeting, has 2 streams of forum: 5th World-China Biosimilars Forum and 4th International Symposium on Biopharmaceutical Innovation and Development.


BioCon China 2018 (April 20-21, Shanghai) will assemble 40+ global and China’s regulators, tech executives and expert scientists from leading biopharmas, and 500+ professional elites, to deliver and discuss efficient and differentiated R&D strategy for biopharmaceuticals.



Conference:5th World-China Biosimilars Forum (WCBF)


Co-Organizer:Shanghai Henlius Biotech,Inc.

Theme: Seek Efficient and Low-Cost Development Strategies from Clinical Stage to Commercialization

Conference Date:April 20-21, 2018

Conference Location:Shanghai, China


Key Reasons Not to Miss WCBF 2018

  1. Keep updated with the latest clinical development requirements of global and China’s biosimilars regulations and guidelines
  2. Discuss the advanced strategy and solutions to enhance biosimilars’ bioprocessing stability and reliability
  3. Learn the leading practices of quality and cost control from clinical development to commercial manufacturing
  4. Summarize the experience from clinical trials’ design, statistics, tests, indications and etc to quicken biosimilars’ clinical development
  5. Overlook the market access and clinical accessibility for future biosimilars



Conference:4th International Symposium on Biopharmaceutical Innovation and Development (ISBID)

Host: Shanghai Jiaotong University School of Pharmacy; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education (ERCCTA)

Organizer: BMAP

Conference DateApril 20-21, 2018

Conference Location:Shanghai, China



What’s New on BioCon ISBID?

  1. Listening to successful experience of regulatory registration from global and China’s biopharmaceuticals
  2. Learning antibody & cell structure design and optimization for early discovery under computer to achieve drug differentiation strategy
  3. Improving the efficiency of biopharmaceuticals’ druggability selection and assessment, to guide clinical trial design
  4. Following up the updated R&D progress of new structural antibody, cell products, I-O combination and innovative formulations
  5. Discussing process challenges and phase achievements of bispecifics, ADC, cell products to speed up development


Who You Will Meet in BioCon China 2018?

  • Executives and Managements of R&D, RA, Quality, BD, Nonclinical/Clinical department from Biopharmaceutical companies
  • Senior Executives and Managements of R&D, BD from Biotechnology Companies
  • CEO, Directors from CRO and CMO
  • Biopharmaceutical Regulators
  • Scientists from Biopharmaceuticals, Translational Medicine, Biological Institutes


As annual meeting, BioCon has gathered 1200+ attendees and 100+ extinguished industrial & regulatory scientists from leading players in the biosimilars sector from China and worldwide in the past 4 years.

Post a Comment

You must be logged in to post a Comment.